This multicenter, randomized, open-label clinical trial evaluated the efficacy and tolerability of intravenous tigecycline compared with oral doxycycline in adults hospitalized with scrub typhus. Participants were randomly assigned to receive either intravenous tigecycline or oral doxycycline. The primary efficacy outcome was time to defervescence, and tolerability was assessed based on reported adverse events.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
27
Doxycycline 100 mg orally every 12 hours for 7 days.
Tigecycline 100 mg intravenously as a loading dose, followed by 50 mg intravenously every 12 hours for 5 days.
Dankuk university hospital
Cheonan, Chungcheongnam-do, South Korea
Inha university hospital
Incheon, South Korea
Gyeonsang National University Hospital
Jinju, South Korea
Defervescence
Time from treatment initiation to defervescence, defined as maintenance of body temperature below 37.3°C for at least 48 consecutive hours without antipyretics.
Time frame: from treatment initiation to defervescence, assessed daily through Day 7
Treatment failure
persistence of fever over 3 days after therapy, but no other cause of fever
Time frame: up to 7 days after treatment initiation
Relapse
relapse on 30th days
Time frame: up to 30 days after treatment initiation
adverse events
Occurrence of treatment-emergent adverse events
Time frame: up to 28 days after treatment initiation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.